LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Home・Aktien・Exelixis Inc

Exelixis Inc

Open

Branche Gesundheitswesen

27.39 3.59

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

26.44

Max

27.35

Schlüsselkennzahlen
By Trading Economics
Einkommen	189M 226M
Verkäufe	212M 637M
KGV Branchendurchschnitt	34.57 103.001
EPS	0.84
Gewinnspanne	35.486
Angestellte	1,310
EBITDA	215M 284M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+6.12 upside

Dividenden
By Dow Jones
Nächstes Ergebnis	30. Okt. 2024

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-191M 7.9B
Vorheriger Eröffnungskurs	23.8
Vorheriger Schlusskurs	27.39

Nachrichtenstimmung

By Acuity

50%

97 / 365 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

25.724 / 26.63 Unterstützung & Widerstand

Exelixis Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Sept. 2024, 01:45 UTC

Ergebnisse

Preview -- Barron's

13. Sept. 2024, 20:03 UTC

Top News

Walgreens to Pay $106.8 Million Over Alleged Fraudulent Healthcare Billings

15. Sept. 2024, 23:47 UTC

Market Talk

Gold Edges Higher Amid Mild Dollar Weakness -- Market Talk

15. Sept. 2024, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Sept. 2024, 23:03 UTC

Market Talk

Australian Bond Traders Watchful as Fed Easing Nears -- Market Talk

15. Sept. 2024, 16:52 UTC

Top News

Boeing Machinist Strike Adds Cash Crunch to New CEO's Rescue Mission -- WSJ

15. Sept. 2024, 09:30 UTC

Top News

Interest Rates Are Too High. The Fed Should Cut by a Half Point. -- WSJ

15. Sept. 2024, 07:00 UTC

Top News

World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna -- Barrons.com

14. Sept. 2024, 14:09 UTC

Top News

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- Update 1 -- WSJ

14. Sept. 2024, 13:25 UTC

Top News

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- WSJ

14. Sept. 2024, 09:30 UTC

Top News

Why a Fed Rate Cut Won't Solve the Housing Wealth Gap -- WSJ

14. Sept. 2024, 09:30 UTC

Top News

Americans Are Falling Behind on Their Bills. Wall Street Is Alarmed. -- WSJ

14. Sept. 2024, 03:00 UTC

Top News

What Scared Ford's CEO in China -- WSJ

14. Sept. 2024, 03:00 UTC

Top News

What Scared Ford's CEO in China -- WSJ -2-

14. Sept. 2024, 00:01 UTC

Top News

Why 96% of Boeing's Machinists Voted to Go on Strike -- Update

13. Sept. 2024, 21:14 UTC

Top News

Why 96% of Boeing's Machinists Voted to Go on Strike -- WSJ

13. Sept. 2024, 21:06 UTC

Top News

Starliner Astronauts Say NASA Ran Short of Time to Test Boeing Craft -- WSJ

13. Sept. 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

13. Sept. 2024, 20:47 UTC

Market Talk

Saudi Arabia Credit Outlook Raised to Positive on Economic Investments -- Market Talk

13. Sept. 2024, 20:44 UTC

Akquisitionen, Fusionen, Übernahmen

Schlumberger Stock Was Once as Hot as Nvidia. Why It's a Buy. -- Barrons.com

13. Sept. 2024, 20:41 UTC

Top News

Berkshire Hathaway's Stock Is So Rich Even Berkshire Is Buying Less of It -- Update

13. Sept. 2024, 20:31 UTC

Ergebnisse

These Stocks Moved the Most Today: Adobe, Boeing, Trump Media, Oracle, Uber, RH, Moderna, Etsy, and More -- Barrons.com

13. Sept. 2024, 20:13 UTC

Akquisitionen, Fusionen, Übernahmen

BlackRock: Expects to Close Previously Announced Acquisition of Global Infrastructure Partners on Oct 1 >BLK

13. Sept. 2024, 20:10 UTC

Akquisitionen, Fusionen, Übernahmen

BlackRock Announces Expected Closing Date For Acquisition Of Global Infrastructure Partners >BLK

13. Sept. 2024, 20:02 UTC

Akquisitionen, Fusionen, Übernahmen

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13. Sept. 2024, 20:02 UTC

Akquisitionen, Fusionen, Übernahmen

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13. Sept. 2024, 19:44 UTC

Market Talk

Treasury Yields Fall as Odds of 50bp Fed Cut Rise -- Market Talk

13. Sept. 2024, 19:20 UTC

Market Talk

Crude-Oil Futures End Week With Small Gains -- Market Talk

13. Sept. 2024, 19:09 UTC

Market Talk

U.S. Natural-Gas Futures Post Weekly Gain -- Market Talk

13. Sept. 2024, 18:01 UTC

Market Talk

Gold Analysts Call For New Leg Of Rally -- Market Talk

Peer-Vergleich

Kursveränderung

Exelixis Inc Prognose

Kursziel

By TipRanks

6.12% Vorteil

12-Monats-Prognose

Durchschnitt 28.08 USD 6.12%

Hoch 33 USD

Tief 25 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Exelixis Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

14 ratings

Buy

Halten

Sell

Basierend auf 14 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Exelixis Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

25.724 / 26.63Unterstützung & Widerstand

Recent bullish events outweigh bearish events.

Bullish events outweigh bearish events.

All events are bullish.

Stimmung

By Acuity

97 / 365 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

EBITDA

Betriebsergebnis

Über Exelixis Inc

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.